I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

AMCP 2026

We will be contributing to topics related to
-
08:30 PM
Duration 60mins Nashville, USA
Real-world persistence, switching, and reinitiation in patients who are on faricimab▼ in the US
Stella Ko, Robert Schuldt, Nicole Bonine, Frank Brodie
Duration 60mins Nashville, USA
IMPACT OF THE ILLINOIS BIOMARKER TESTING LAW ON UTILIZATION IN ADVANCED NON-SMALL CELL LUNG CANCER AND METASTATIC COLORECTAL CANCER PATIENTS
Stella Ko, Tu My To, William B. Wong
09:30 PM
Duration 60mins Nashville, USA
Projecting potential annual event and cost savings with omalizumab from the reduction in food allergy reactions in the United States population
Fadoua El Moustaid, Arpamas Seetasith, Karina Raimundo, Fatima Dawod, Olivia Mooney, Rina Lukanova, Dawn Sibanda
Duration 60mins Nashville, USA
Better Improvement for Omalizumab Versus Dupilumab/Remibrutinib for Patients With Chronic Spontaneous Urticaria: Week 12 Disease Activity Matching-Adjusted Indirect Comparison
Karina Raimundo, Giselle Mosnaim, Michael Holden, Benjamin L. Trzaskoma, Pranil Raut, Arpamas Seetasith, Jonathan A. Bernstein
Duration 60mins Nashville, USA
Improved Outcomes, Emergency Visits, and Quality of Life for Patients With Food Allergy on Omalizumab Monotherapy
Arpamas Seetasith, Edwin H. Kim, Sayantani Sindher, Fatima Dawod, Olivia Mooney, Rina Lukanova, Dawn Sibanda, Matthew Greenhawt
04:00 PM
Duration 60mins Nashville, USA
Real-World Impact of Discontinuing Ocrelizumab on Healthcare Resource Utilization and Cost Among Older Adult Patients With Multiple Sclerosis in the United States
Elmor D. Pineda, Achal Patel, Danny Sheinson, Zhiyu Xia, Ibraheem Abioye
06:00 PM
Duration 60mins Nashville, USA
Fixed-duration subcutaneous mosunetuzumab is cost-effective compared with alternative novel treatment options in third-line or later follicular lymphoma in the United States
Nilanjan Ghosh, Katherine L Rosettie, David Elsea, Mei Wu, Esprit Ma
Duration 60mins Nashville, USA
Fixed-duration subcutaneous mosunetuzumab has the lowest total cost of care compared with alternative novel treatment options in third-line or later follicular lymphoma in the United States
Nilanjan Ghosh, Katherine L Rosettie, Mei Wu, Esprit Ma
Duration 60mins Nashville, USA
Cost-effectiveness analysis of obinutuzumab for the treatment of Lupus Nephritis in the United States
Anisha M. Patel, Katherine L. Rosettie, Fadoua El Moustaid, Jesse Sussell, Carolina Heuser, William F. Pendergraft, Amit Saxena
Coming soon